Meredith M. Regan, ScD, on Early Breast Cancer: Update on the TEXT and SOFT Trials

Posted: Thursday, December 7, 2017

Meredith M. Regan, ScD, of the Dana-Farber Cancer Institute, discusses study findings comparing adjuvant aromatase inhibitor exemestane plus ovarian function suppression (OFS) vs tamoxifen plus OFS in premenopausal women with HR+ early breast cancer.